PT2556091T - Anticorpo reconhecedor do fator inibitório da leucemia (lif) humano e uso de anticorpos anti-lif no tratamento de doenças associadas à proliferação celular indesejada - Google Patents

Anticorpo reconhecedor do fator inibitório da leucemia (lif) humano e uso de anticorpos anti-lif no tratamento de doenças associadas à proliferação celular indesejada

Info

Publication number: PT2556091T
Authority: PT; Portugal
Prior art keywords: lif; treatment; cell proliferation; diseases associated; inhibitory factor
Prior art date: 2010-04-05

Application number

PT117156760T

Other languages

English (en)

Inventor

Seoane Suarez Joan

Anido Folgueira Judit

Saez Borderias Andrea

Original Assignee

Fund Privada Inst D'investigacio Oncologica De Vall D'hebron (Vhio)

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-04-05

Filing date

2011-04-05

Publication date

2017-01-03

2011-04-05 Application filed by Fund Privada Inst D'investigacio Oncologica De Vall D'hebron (Vhio) filed Critical Fund Privada Inst D'investigacio Oncologica De Vall D'hebron (Vhio)

2017-01-03 Publication of PT2556091T publication Critical patent/PT2556091T/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5415—Leukaemia inhibitory factor [LIF]

PT117156760T 2010-04-05 2011-04-05 Anticorpo reconhecedor do fator inibitório da leucemia (lif) humano e uso de anticorpos anti-lif no tratamento de doenças associadas à proliferação celular indesejada PT2556091T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP10380049A EP2371860A1 (en)	2010-04-05	2010-04-05	Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation

Publications (1)

Publication Number	Publication Date
PT2556091T true PT2556091T (pt)	2017-01-03

Family

ID=42338260

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT117156760T PT2556091T (pt)	2010-04-05	2011-04-05	Anticorpo reconhecedor do fator inibitório da leucemia (lif) humano e uso de anticorpos anti-lif no tratamento de doenças associadas à proliferação celular indesejada

Country Status (25)

Country	Link
US (3)	US8926956B2 (pt)
EP (3)	EP2371860A1 (pt)
JP (2)	JP6289906B2 (pt)
KR (5)	KR102294207B1 (pt)
CN (2)	CN103797031A (pt)
AU (1)	AU2011237922B2 (pt)
BR (1)	BR112012025517B1 (pt)
CA (1)	CA2797257A1 (pt)
CY (1)	CY1119451T1 (pt)
DK (1)	DK2556091T3 (pt)
EA (2)	EA036698B9 (pt)
ES (1)	ES2608699T3 (pt)
HK (3)	HK1223384A1 (pt)
HR (1)	HRP20161736T1 (pt)
HU (1)	HUE030578T2 (pt)
IL (3)	IL222270A (pt)
LT (1)	LT2556091T (pt)
MX (2)	MX365054B (pt)
PL (1)	PL2556091T3 (pt)
PT (1)	PT2556091T (pt)
RS (1)	RS55539B1 (pt)
SG (1)	SG184429A1 (pt)
SI (1)	SI2556091T1 (pt)
SM (1)	SMT201600468T1 (pt)
WO (1)	WO2011124566A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUE040063T2 (hu) *	2005-07-19	2019-02-28	Stemgen S P A	Tumor õssejtek tumorképzõ potenciáljának gátlása BMP-4 segítségével
ES2363358B1 (es) *	2009-04-03	2012-06-21	FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al	Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
EP2371860A1 (en) *	2010-04-05	2011-10-05	Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron	Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
WO2015040243A2 (en) *	2013-09-23	2015-03-26	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for targeting tumor microenvironment and for preventing metastasis
TWI486172B (zh) *	2013-11-08	2015-06-01	Univ Chang Gung	鼻咽癌治療的醫藥
AU2015314980A1 (en) *	2014-09-10	2017-03-02	The Regents Of The University Of California	Targeting K-Ras-mediated signaling pathways and malignancy by anti-hLIF antibodies
CA2981173C (en)	2015-03-23	2024-01-02	Evestra, Inc.	Novel cytotoxic agents that preferentially target leukemia inhibitory factor (lif) for the treatment of malignancies and as new contraceptive agents
EP3173483A1 (en) *	2015-11-27	2017-05-31	Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron	Agents for the treatment of diseases associated with undesired cell proliferation
CN111868086A (zh) *	2016-12-19	2020-10-30	马赛克生物医学一人有限责任公司	抗lif抗体及其用途
WO2018115960A1 (en)	2016-12-19	2018-06-28	Mosaic Biomedicals, S.L.	Antibodies against lif and uses thereof
WO2018167283A1 (en)	2017-03-17	2018-09-20	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
EP3774895A1 (en)	2018-04-12	2021-02-17	MedImmune Limited	Combination of lif inhibitors and pd-1 axis inhibitors for use in treating cancer
KR20210008514A (ko) *	2018-05-14	2021-01-22	메디뮨 리미티드	Lif에 대한 항체 및 이의 투여 형태
KR20210022065A (ko) *	2018-06-18	2021-03-02	메디뮨 리미티드	암을 치료하는 데 사용하기 위한 lif 억제제와 백금-기반 항신생물제의 조합
KR20220087457A (ko) *	2019-09-29	2022-06-24	자코바이오 파마슈티칼스 컴퍼니 리미티드	Lif에 특이적인 결합 분자 및 이의 용도
CN111020030A (zh) *	2019-12-03	2020-04-17	中山大学	一种骨肉瘤干细胞标志物及其应用、试剂盒
CN111378036B (zh) *	2020-01-09	2021-08-10	北京浩古元方生物医药科技有限公司	一种抗人白血病抑制因子单克隆抗体的制备方法及其应用
CN112294812B (zh) *	2020-11-18	2022-08-16	新乡医学院	一种小分子抑制剂在制备抗肿瘤药物方面的应用
CN114672460B (zh) *	2021-12-21	2023-06-23	中国人民解放军军事科学院军事医学研究院	一种靶向cd44的异质型cic细胞模型的制备方法及应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en)	1987-03-18	1988-09-22	Medical Research Council	Altered antibodies
GB9004890D0 (en)	1990-03-05	1990-05-02	Heath John K	Leukaemia inhibitory factor
JP4124480B2 (ja)	1991-06-14	2008-07-23	ジェネンテック・インコーポレーテッド	免疫グロブリン変異体
JPH05304986A (ja)	1992-04-28	1993-11-19	Tosoh Corp	ｇｐ１３０蛋白質に対するモノクロ−ナル抗体
AU4231393A (en)	1992-05-08	1993-12-13	Genentech Inc.	Antibodies to leukemia inhibitory factor
WO1993023665A1 (en)	1992-05-15	1993-11-25	Re/Map Incorporated	Electromagnetic shielding for a liquid conditioning device
EP0714409A1 (en)	1993-06-16	1996-06-05	Celltech Therapeutics Limited	Antibodies
CA2214636C (en) *	1995-04-24	2009-12-22	Genentech, Inc.	Use of leukemia inhibitory factor and endothelin antagonists
US20050147609A1 (en)	1998-05-15	2005-07-07	Genentech, Inc.	Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis
ES2694002T3 (es)	1999-01-15	2018-12-17	Genentech, Inc.	Polipéptido que comprende una región Fc de IgG1 humana variante
US7084257B2 (en)	2001-10-05	2006-08-01	Amgen Inc.	Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
AU2003218456A1 (en)	2002-04-01	2003-10-20	Human Genome Sciences, Inc.	Antibodies that specifically bind to gmad
AU2003262717A1 (en) *	2002-08-15	2004-03-03	Genzyme Corporation	Brain endothelial cell expression patterns
US7361740B2 (en)	2002-10-15	2008-04-22	Pdl Biopharma, Inc.	Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2005030803A1 (en)	2003-09-29	2005-04-07	The Walter And Eliza Hall Institute Of Medical Research	Therapeutic molecules
EP1752536A4 (en)	2004-05-11	2008-04-16	Alphagen Co Ltd	POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME
EP1612558A1 (en)	2004-06-30	2006-01-04	Academisch Ziekenhuis Leiden	Method for detecting gluten
US8768629B2 (en)	2009-02-11	2014-07-01	Caris Mpi, Inc.	Molecular profiling of tumors
CA2665447A1 (en)	2006-10-04	2008-04-10	The Scripps Research Institute	Human antibodies neutralizing human metapneumovirus
CN101440128A (zh) *	2007-11-21	2009-05-27	中国人民解放军第二军医大学	人脑胶质瘤中差异表达的蛋白及其用途
WO2010054499A1 (en) *	2008-11-11	2010-05-20	Telefonaktiebolaget L M Ericsson (Publ)	A dpd system with multiple transmitter paths
ES2363358B1 (es)	2009-04-03	2012-06-21	FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al	Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
WO2011057144A2 (en)	2009-11-06	2011-05-12	La Jolla Institute For Allergy And Immunology	Methods for modulating lif activity, treating immune disorders and diseases, and stimulatings immune responses
CN102167742B (zh)	2010-02-25	2014-05-14	上海百迈博制药有限公司	一种全人源抗her2单克隆抗体、其制备方法及用途
EP2371860A1 (en)	2010-04-05	2011-10-05	Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron	Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
TWI486172B (zh)	2013-11-08	2015-06-01	Univ Chang Gung	鼻咽癌治療的醫藥

2010
- 2010-04-05 EP EP10380049A patent/EP2371860A1/en not_active Withdrawn
2011
- 2011-04-05 AU AU2011237922A patent/AU2011237922B2/en not_active Ceased
- 2011-04-05 EA EA201201373A patent/EA036698B9/ru not_active IP Right Cessation
- 2011-04-05 CN CN201180027552.6A patent/CN103797031A/zh active Pending
- 2011-04-05 MX MX2015008974A patent/MX365054B/es unknown
- 2011-04-05 LT LTEP11715676.0T patent/LT2556091T/lt unknown
- 2011-04-05 ES ES11715676.0T patent/ES2608699T3/es active Active
- 2011-04-05 MX MX2012011636A patent/MX2012011636A/es active IP Right Grant
- 2011-04-05 JP JP2013503084A patent/JP6289906B2/ja active Active
- 2011-04-05 KR KR1020207028482A patent/KR102294207B1/ko active IP Right Grant
- 2011-04-05 EP EP16154907.6A patent/EP3045473A1/en not_active Withdrawn
- 2011-04-05 KR KR1020177031786A patent/KR20170125137A/ko not_active Application Discontinuation
- 2011-04-05 CN CN201810679717.1A patent/CN109320609A/zh active Pending
- 2011-04-05 CA CA2797257A patent/CA2797257A1/en not_active Abandoned
- 2011-04-05 SG SG2012073557A patent/SG184429A1/en unknown
- 2011-04-05 EA EA202092276A patent/EA202092276A3/ru unknown
- 2011-04-05 RS RS20161123A patent/RS55539B1/sr unknown
- 2011-04-05 KR KR1020127028860A patent/KR20130121679A/ko not_active Application Discontinuation
- 2011-04-05 BR BR112012025517-7A patent/BR112012025517B1/pt not_active IP Right Cessation
- 2011-04-05 US US13/261,464 patent/US8926956B2/en active Active
- 2011-04-05 PL PL11715676T patent/PL2556091T3/pl unknown
- 2011-04-05 KR KR1020197015171A patent/KR20190061098A/ko not_active Application Discontinuation
- 2011-04-05 PT PT117156760T patent/PT2556091T/pt unknown
- 2011-04-05 HU HUE11715676A patent/HUE030578T2/en unknown
- 2011-04-05 SI SI201131028A patent/SI2556091T1/sl unknown
- 2011-04-05 DK DK11715676.0T patent/DK2556091T3/en active
- 2011-04-05 KR KR1020187018882A patent/KR20180078352A/ko active Application Filing
- 2011-04-05 EP EP11715676.0A patent/EP2556091B1/en active Active
- 2011-04-05 WO PCT/EP2011/055253 patent/WO2011124566A1/en active Application Filing
2012
- 2012-10-09 IL IL222270A patent/IL222270A/en active IP Right Grant
2013
- 2013-07-10 HK HK16111721.5A patent/HK1223384A1/zh unknown
- 2013-07-10 HK HK13108092.5A patent/HK1180702A1/zh not_active IP Right Cessation
2014
- 2014-11-04 HK HK14111011.6A patent/HK1208469A1/xx unknown
2015
- 2015-01-05 US US14/589,033 patent/US20150139989A1/en not_active Abandoned
- 2015-10-07 IL IL241952A patent/IL241952A/en active IP Right Grant
2016
- 2016-07-01 JP JP2016131179A patent/JP6483059B2/ja active Active
- 2016-12-16 HR HRP20161736TT patent/HRP20161736T1/hr unknown
- 2016-12-22 SM SM201600468T patent/SMT201600468T1/it unknown
- 2016-12-22 CY CY20161101328T patent/CY1119451T1/el unknown
2017
- 2017-09-25 IL IL254664A patent/IL254664B/en unknown
2018
- 2018-05-14 US US15/978,362 patent/US10968273B2/en active Active

Also Published As

Publication number	Publication date
EP2371860A1 (en)	2011-10-05
US20190119373A1 (en)	2019-04-25
EA201201373A1 (ru)	2013-04-30
JP2013523796A (ja)	2013-06-17
EP2556091A1 (en)	2013-02-13
EA036698B9 (ru)	2021-02-25
IL241952A (en)	2017-10-31
IL254664A0 (en)	2017-11-30
KR20170125137A (ko)	2017-11-13
KR20190061098A (ko)	2019-06-04
HK1223384A1 (zh)	2017-07-28
US10968273B2 (en)	2021-04-06
US20130142808A1 (en)	2013-06-06
JP2017019775A (ja)	2017-01-26
CN103797031A (zh)	2014-05-14
KR102294207B1 (ko)	2021-08-26
MX365054B (es)	2019-05-21
HK1208469A1 (en)	2016-03-04
SI2556091T1 (sl)	2017-02-28
EP3045473A1 (en)	2016-07-20
LT2556091T (lt)	2016-12-27
EA036698B1 (ru)	2020-12-09
HUE030578T2 (en)	2017-06-28
US20150139989A1 (en)	2015-05-21
KR20180078352A (ko)	2018-07-09
RS55539B1 (sr)	2017-05-31
CY1119451T1 (el)	2018-03-07
PL2556091T3 (pl)	2017-04-28
CA2797257A1 (en)	2011-10-13
IL254664B (en)	2022-03-01
HRP20161736T1 (hr)	2017-02-10
BR112012025517A2 (pt)	2017-11-28
SG184429A1 (en)	2012-11-29
WO2011124566A1 (en)	2011-10-13
IL222270A (en)	2016-06-30
JP6483059B2 (ja)	2019-03-13
CN109320609A (zh)	2019-02-12
AU2011237922B2 (en)	2014-07-10
EA202092276A3 (ru)	2021-04-30
IL222270A0 (en)	2012-12-31
ES2608699T3 (es)	2017-04-12
MX2012011636A (es)	2013-04-03
KR20130121679A (ko)	2013-11-06
SMT201600468T1 (it)	2017-03-08
DK2556091T3 (en)	2017-01-16
BR112012025517B1 (pt)	2021-08-31
KR20200119344A (ko)	2020-10-19
AU2011237922A1 (en)	2012-11-01
US8926956B2 (en)	2015-01-06
EA202092276A2 (ru)	2021-01-29
EP2556091B1 (en)	2016-09-28
HK1180702A1 (zh)	2013-10-25
JP6289906B2 (ja)	2018-03-07

Publication	Publication Date	Title
IL254664B (en)	2022-03-01	An antibody that recognizes human leukemia inhibitory factor (lif) and the use of anti-lif antibodies in the treatment of diseases associated with unwanted cell proliferation
CY2019008I1 (el)	2019-11-27	Χρηση τροποποιημενων απο χιμαιρικο αντιγονικο υποδοχεα τ κυτταρων στη θεραπευτικη αγωγη καρκινου
EP3043819A4 (en)	2017-04-05	Anti-vstm5 antibodies and the use thereof in therapy and diagnosis
SG178991A1 (en)	2012-04-27	Anti-gitr antibodies
HK1198469A1 (en)	2015-05-08	Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease -icos
IL228813B (en)	2018-07-31	A polypeptide containing a first and second immunoglobulin each containing a single variable site and its use in the treatment of diseases
EP2756073A4 (en)	2015-05-06	MANIPULATED TISSUE FOR IN VITRO RESEARCH, ARRAYS AND METHOD FOR THE PRODUCTION THEREOF
CA2840307C (en)	2021-10-19	Progenitor cells of mesodermal lineage
ZA201109384B (en)	2012-09-26	Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases
WO2011126864A3 (en)	2012-04-19	Cancer treatment with recombinant vector
HK1163119A1 (en)	2012-09-07	Anti cxcr4 antibodies and their use for the treatment of cancer cxcr4
ZA201307641B (en)	2015-04-29	Human tissue factor antibody and uses thereof
HK1208629A1 (en)	2016-03-11	Hgh-xten fusion protein and its use in the treatment of growth hormone deficiency hgh-xten
IL223667B (en)	2018-03-29	4a100s antibodies and medical uses thereof
PL2700708T3 (pl)	2018-01-31	Zwiększanie zdolności limfocytów T do stymulacji ludzkiego antygenu prezentującego komórki in vitro oraz in vivo i jego zastosowanie w szczepieniu
HK1179997A1 (en)	2013-10-11	Neuregulin antagonists and use thereof in treating cancer
PL2668205T3 (pl)	2017-09-29	Peptydy pochodzące z ludzkiej laktoferyny i ich zastosowanie
EP2632939A4 (en)	2014-05-14	CANCER TARGETING PEPTIDES AND USES THEREOF IN THE TREATMENT AND DIAGNOSIS OF CANCER
EP2744786A4 (en)	2015-01-07	SUBSTITUTED 2-IMIDAZOLIDINONE AND 2-IMIDAZOLONE AND THEIR USE IN THE TREATMENT OF CANCER
EP3052109B8 (en)	2021-06-23	Therapy with cells from human placenta and hematopoietic cells
ZA201401800B (en)	2015-07-29	Novel plant defensins and use in the treatment of proliferative diseases
DK2665746T3 (en)	2021-02-01	Antibodies against the s100p protein for the treatment and diagnosis of cancer
GB201015789D0 (en)	2010-10-27	Peptides and their use in the treatment
ZA201309332B (en)	2014-08-27	Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
GB201001170D0 (en)	2010-03-10	Novel peptides and their use in therepy and diagnosis